Please assess the completion status of the following clinical trial:

Trial Title: Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range 14-70 years old; ECOG performance status 0-2.~* Estimated survival time \> 6 months.~* Histological confirmed diffuse large B cell lymphoma.~* Have taken first-line chemotherapy regimen and failed.~* None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal.~* At least one measurable lesion.~* None of other serious diseases, cardiopulmonary function is normal.~* Pregnancy test of women at reproductive age must be negative.~* Patients could be followed up.~* None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.~* Volunteers who signed informed consent.~Exclusion Criteria:~* Disagreement on blood sample collection.~* Patients allergic of any of drug in this regimen or with metabolic disorder.~* Pregnant or lactating women.~* Serious medical illness likely to interfere with participation.~* Serious infection.~* Primitive or secondary tumors of central nervous system.~* Chemotherapy or radiotherapy contraindication.~* The evidence of CNS metastasis.~* History of peripheral nervous disorder or dysphrenia.~* Patients participating in other clinical trials.~* Patients taking other antitumor drugs.~* Patients estimated to be unsuitable by investigator.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Apatinib (Type: EXPERIMENTAL): Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.

Based on this trial design, predict the completion outcome and termination type (if applicable).